What is ImmunityBio, Inc.'s equity method income?

ImmunityBio, Inc. (IBRX) reported equity method income of $0 in Q4 2025.

What is the long-term trend for ImmunityBio, Inc.'s equity method income?

Over 4 years (2021 to 2025), ImmunityBio, Inc.'s equity method income has grown at a -100.0% compound annual growth rate (CAGR), from -$803K to $0.

What does equity method income mean?

The company's proportional share of net income or loss from unconsolidated affiliates and joint ventures accounted for under the equity method.

ImmunityBio, Inc. IBRX Equity Method Income

Discontinued — last reported Q4 '25

Equity Method Income at other companies

Nextra EnergyNEE

$171M+126%

Mid-America Apartment CommunitiesMAA

$266K-42.8%

FlowserveFLS

$2.99M-47.8%

Willis Towers WatsonWTW

-$3M-400%

TechnipFMCFTI

$4.5M-52.1%

WelltowerWELL

-$1.69M-233%

Segments

By segment

See full

Segment Reporting$0—

Other financials

Income statement

See full

Revenue$44.2M+168%

Gross profit$44.0M+167%

Operating income-$69.8M-8.3%

Net income-$632.8M-388%

EPS (diluted)-$0.62-313%

Balance sheet

See full

Cash & equivalents$205.2M+238%

Total debt$445.4M+32.2%

Total equity-$870.0M-47.1%

Total assets$646.6M+113%

Cash flow

See full

Operating cash flow-$75.4M+12.3%

CapEx$1.8M+58.4%

Free cash flow-$77.1M+11.4%

Valuation

See full

Market cap$7.71B+208%

Enterprise value$7.95B+187%

P/S54.7×-25.4×

Profitability

See full

Gross margin99.3%-0.5pp

Operating margin-185.4%-83.3pp

Net margin-606.2%-212pp

FCF margin-212%-95.8pp

Returns & leverage

See full

Return on equity-119.3%—

Debt / equity0.1×—

Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.

The official record: ImmunityBio, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s equity method income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ImmunityBio, Inc.'s equity method income?: ImmunityBio, Inc. (IBRX) reported equity method income of $0 in Q4 2025.
What is the long-term trend for ImmunityBio, Inc.'s equity method income?: Over 4 years (2021 to 2025), ImmunityBio, Inc.'s equity method income has grown at a -100.0% compound annual growth rate (CAGR), from -$803K to $0.
What does equity method income mean?: The company's proportional share of net income or loss from unconsolidated affiliates and joint ventures accounted for under the equity method.